Table 2.

Summary Statistics of Pharmacokinetic Parameters of Vilaprisan in Plasma

Parameter	Geometric Mean	Geometric CV (%)	Arithmetic Mean	Arithmetic SD	Min	Median	Max
AUC0‐24 (μg · h/L)	89.2	23.5	91.3	20.4	53.1		135
AUC0‐24,md (μg · h/L)	258	39.8	276	109	148		505
Cav,md (μg/L)	10.8	39.8	11.5	4.55	6.18		21.0
Cmax (μg/L)	12.1	29.8	12.5	3.04	5.77		15.8
Cmax,md (μg/L)	22.5	27.8	23.3	6.73	16.0		35.4
Cmin,md (μg/L)	7.52	45.5	8.22	3.83	4.14		15.7
tmax (h)					1.00	1.50	6.00
tmax,md (h)					1.00	1.50	2.50
t1/2,md (h)	43.4	22.9	44.5	10.3	30.8		66.8
tlast,md (h)					168	336	336
RAAUC	2.89	26.7	2.98	0.767	1.67		4.66
RACmax	1.86	25.2	1.92	0.554	1.43		3.36
CLmd/F (L/h)	7.75	39.8	8.27	3.10	3.96		13.5

AUC, area under the concentration vs time curve; AUC_0‐24, AUC from time zero to 24 h after dosing; C_av,md, average concentration; C_max, maximum observed concentration; C_min,md, minimum observed concentration above lower limit of quantitation in the dose interval after multiple dosing; CL_md/F, apparent oral clearance calculated from dose and AUC_0‐24,md; CV, coefficient of variation; md, multiple dose; R_AAUC, accumulation ratio calculated as AUC_0‐24,md/AUC_0‐24; R_AC_max, accumulation ratio calculated as C_max,md/C_max; SD, standard deviation; t_1/2,md, terminal half‐life after multiple dose; t_last,md, time of last observed concentration value above lower limit of quantitation; t_max, time to reach C_max.

Data are presented on the pharmacokinetic analysis set (N = 11).